Cullinan Therapeutics, Inc.
corporate_fare Company Profile
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CGEM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CGEM spans 8-K, 10-Q.
Recent high-impact activity:
- Zipalertinib NDA Filed Under FDA Real-Time Review for First-Line EGFR ex20ins NSCLC
- Velinotamig Drives Complete Renal Responses in Refractory SLE; 8 of 9 Patients Improve
- Zipalertinib Shows 30% Intracranial Response Rate in Brain-Metastatic EGFR NSCLC
- Cullinan Initiates NDA Submission for Zipalertinib Combo in First-Line EGFR ex20ins NSCLC Under FDA RTOR
- Cullinan Sets Q4 Data Readouts for Three T Cell Engagers, FDA Meeting Clears Path for CLN-049 Phase 2
Financial Snapshot
Short Interest & Short Volume
13.33 days to coverFINRA reported short interest of 7,928,668 shares in CGEM as of the October 30, 2026 settlement, a 3.8% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 20, 2026, 57.6% of CGEM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.